Sensorion Dirección

Dirección controles de criterios 2/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Amit Munshi

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	less than a year
Participación del CEO	n/a
Permanencia media de la dirección	2.8yrs
Promedio de permanencia en la Junta Directiva	5.7yrs

Actualizaciones recientes de la dirección

Recent updates

CEO

Amit Munshi (57 yo)

less than a year

Permanencia

Mr. Amit D. Munshi, MBA, is Chairman of Sensorion SA from April 1, 2025 and serves as its Interim CEO since February 17, 2026. Mr. Munshi has been the Director of Inhibikase Therapeutics Inc. since October...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Amit Munshi	Chairman & Interim CEO	less than a year	sin datos	sin datos
Laurene Danon	Chief Financial Officer	1.8yrs	sin datos	sin datos
Bernd Schmidt	Chief Technical Officer	2.3yrs	sin datos	sin datos
Geraldine Honnet	Chief Medical Officer	6.2yrs	sin datos	sin datos
Christine Bec	Head of CMC Gene Therapy	6.2yrs	sin datos	sin datos
Stephanie Filipe	Head of Business Operations & Portfolio Management	4.8yrs	sin datos	sin datos
Laurent Desire	Head of Preclinical Development	3.3yrs	sin datos	sin datos
Rachel Cooper	Head of Audiology	2.4yrs	sin datos	sin datos

2.8yrs

Permanencia media

Equipo directivo experimentado: El equipo directivo de RFM se considera experimentado (2.8 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Amit Munshi	Chairman & Interim CEO	1yr	sin datos	sin datos
Robert Dow	Member of Scientific Advisory Board	5.7yrs	sin datos	sin datos
Khalil Barrage	Director	6.8yrs	sin datos	sin datos
Cédric Moreau	Director	6.8yrs	sin datos	sin datos
Alain Fischer	Member of Scientific Advisory Board	5.7yrs	sin datos	sin datos
Julien Miara	Director	6.8yrs	sin datos	sin datos
Eric de La Fortelle	Independent Director	no data	sin datos	sin datos
Aniz Girach	Independent Director	4.3yrs	sin datos	sin datos
Christine Petit	Chair of Scientific Advisory Board	7.9yrs	sin datos	sin datos
Hernán López-Schier	Member of Scientific Advisory Board	5.7yrs	sin datos	sin datos
Paul Avan	Member of Scientific Advisory Board	5.7yrs	sin datos	sin datos
Diane Lazard	Member of Scientific Advisory Board	5.7yrs	sin datos	sin datos

5.7yrs

Permanencia media

57.5yo

Promedio de edad

Junta con experiencia: La junta directiva de RFM se considera experimentada (5.7 años de antigüedad promedio).

Análisis de la empresa y estado de los datos financieros

Datos	Última actualización (huso horario UTC)
Análisis de la empresa	2026/04/30 21:04
Precio de las acciones al final del día	2026/04/30 00:00
Beneficios	2025/12/31
Ingresos anuales	2025/12/31

Fuentes de datos

Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.

Paquete	Datos	Marco temporal	Ejemplo Fuente EE.UU. ^*
Finanzas de la empresa	10 años	Cuenta de resultados Estado de tesorería Balance	Formulario SEC 10-K Formulario SEC 10-Q
Estimaciones del consenso de analistas	+3 años	Previsiones financieras Objetivos de precios de los analistas	Informes de análisis Blue Matrix
Precios de mercado	30 años	Precios de las acciones Dividendos, escisiones y acciones	Datos de mercado ICE Formulario S-1 de la SEC
Propiedad	10 años	Accionistas principales Información privilegiada	Formulario SEC 4 Formulario SEC 13D
Gestión	10 años	Equipo directivo Consejo de Administración	Formulario SEC 10-K Formulario SEC DEF 14A
Principales avances	10 años	Anuncios de empresas	Formulario SEC 8-K

^* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.

A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.

Modelo de análisis y copo de nieve

Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.

Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.

Métricas industriales y sectoriales

Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.

Fuentes analistas

Sensorion SA está cubierta por 8 analistas. 5 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.

Analista	Institución
Jack Allen	Baird
Janani Sundararajan	Chardan Capital Markets, LLC
Yevgeniya Livshits	Chardan Capital Markets, LLC

Sensorion Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Sensorion SA, Annual General Meeting, May 11, 2026

Sensorion Sa Announces Stepping Down of Nawal Ouzren as Director on the Board

Sensorion SA, Annual General Meeting, May 12, 2025

Sensorion Announces Board Changes

Sensorion Announces Appointment of Laurene Danon as Chief Financial Officer

Sensorion SA, Annual General Meeting, May 29, 2024

Recent updates

Sensorion SA, Annual General Meeting, May 11, 2026

Sensorion Reports Six-Month Update from the Audiogene Phase 1/2 Trial of SENS-501 and Advances GJB2-GT (SENS-601) Toward First-In-Human Clinical Development

Sensorion Sa Announces Stepping Down of Nawal Ouzren as Director on the Board

Sensorion SA has filed a Follow-on Equity Offering in the amount of €60 million.

Sensorion Reports Independent Data Monitoring Committee Raises No Safety Concerns and Agrees to Continue SENS-501'S Audiogene Phase 1/2 Trial

Sensorion Completes Patient Enrollment of the Second Cohort in Audiogene Phase 1/2 Gene Therapy Clinical Trial

Sensorion Announces Preliminary Positive Data from the First Cohort of the Audiogene Phase 1/2 Gene Therapy Clinical Trial

Sensorion SA, Annual General Meeting, May 12, 2025

Sensorion Announces Board Changes

Sensorion Announces the End of Patient Inclusion in NOTOXIS Phase 2a Clinical Trial of Sens-401 for the Prevention of Cisplatin-Induced Ototoxicity

Sensorion Receives Positive Recommendation from Data Monitoring Committee of Sens-501’S Audiogene Phase 1/2 Clinical Trial

Sensorion Announces Completion of Enrollment of the First Cohort of the Audiogene Phase 1/2 Gene Therapy Clinical Trial

Sensorion Reports Data in the Audiogene Phase 1/2 Gene Therapy Clinical Trial

Sensorion Announces Positive Recommendation From the Data Safety Monitoring Board (DSMB) Regarding the Continuation of NOTOXIS, its Phase 2a Clinical Trial of SENS-401 in Cisplatin-Induced Ototoxicity

Sensorion Announces New Positive Secondary Efficacy Endpoints Data from Sens-401 Phase 2A Clinical Trial for the Preservation of Residual Hearing Loss

Sensorion Announces Appointment of Laurene Danon as Chief Financial Officer

Sensorion SA, Annual General Meeting, May 29, 2024

Sensorion SA has completed a Follow-on Equity Offering in the amount of €15.482057 million.

Sensorion Meets Primary Endpoint for Sens-401 Phase 2A Clinical Study for Residual Hearing Preservation

Sensorion SA to Report Fiscal Year 2023 Results on Mar 14, 2024

Sensorion Announces the Completion of Patient Inclusion in Phase 2A Clinical Trial of Sens-401 for Residual Hearing Preservation After Cochlear Implantation

Sensorion Appoints Federico Mingozzi as Non-Executive Director to the Board of Directors

Sensorion Announces Approval to Initiate Lead Gene Therapy Candidate Sens-501 into a Phase 1/2 Clinical Trial in Some European Countries

Sensorion SA Appoints Bernd Schmidt as New Chief Technical Officer

Sensorion SA, Annual General Meeting, Dec 20, 2023

Sensorion SA announced that it has received €33.214286 million in funding from Sofimac Innovation SAS, The Invus Group, LLC, Redmile Group, LLC

Sensorion SA to Report Q2, 2023 Results on Sep 18, 2023

Sensorion Submits Clinical Trial Application for OTOF-GT, its Lead Gene Therapy Candidate, in Europe

Sensorion Sa Submits Clinical Trial Application for Lead Gene Therapy Candidate Otof-Gt in the Uk

Sensorion Reports Positive Efficacy Data from SENS-401 Phase 2a Clinical Study

Sensorion SA Announces First Patient Enrolled in Phase 2a Proof of Concept Clinical Trial of SENS-401 in Cisplatin-Induced Ototoxicity

Sensorion Announces US FDA Grants Rare Pediatric Disease Designation to Otof-Gt for the Treatment of Otoferlin Gene-Mediated Hearing Loss

Sensorion SA Announces Approval to Initiate amended Phase 2a Proof of Concept Clinical Trial of SENS-401 in Cisplatin-Induced Ototoxicity in France

Sensorion Announces First Patient Enrolled in Proof-of-Concept Clinical Trial of SENS-401 for Residual Hearing Preservation During Cochlear Implantation

Sensorion SA to Report First Half, 2022 Results on Sep 22, 2022

Sensorion Announces Approval in Australia to Initiate Proof of Concept Clinical Trial of SENS-401 for Residual Hearing Preservation During Cochlear Implantation

Sensorion Announces Approval in France to Initiate Proof of Concept Clinical Trial of SENS-401 for Residual Hearing Preservation During Cochlear Implantation

Sensorion SA, Annual General Meeting, May 31, 2022

Sensorion SA to Report Fiscal Year 2021 Results on Oct 31, 2022

Sensorion SA Updates on SENS-401 Phase 2 Trial in Sudden Sensorineural Hearing Loss

Sensorion Announces Regulators Approval for Sensorion’s Amendment to Phase 2 Audible-S Trial of SENS-401 in Sudden Sensorineural Hearing Loss

Sensorion Presents New Preclinical Data on SENS-401 at ARO 2021

Sensorion Announces Third Gene Therapy Collaboration with Institut Pasteur Targeting Important Pediatric and Adult Deafness Segments

Sensorion Announces Preclinical Data Demonstrating SENS-401's Potential to Preserve Residual Hearing After Cochlear Implantation

Sensorion Provides an Update on Plans and Progress in the Development of SENS-401 for the Prevention of Hearing Loss

Sensorion SA announced that it expects to receive €4.999999 million in funding from Sonova Holding AG

Sensorion and Novasep Announce Signature of A Gene Therapy Product Development and Manufacturing Agreement

Sensorion SA has completed a Follow-on Equity Offering in the amount of €31.0012 million.

CEO